InterCure's 2025 Revenue Jumps 13% to NIS 270M, Achieves Positive Operating Cash Flow
INCR sits 24% above its 52-week low of $0.68.
Summary
InterCure announced strong financial and operating results for 2025, reporting over NIS 270 million in revenue, a 13% increase from 2024, and a significant swing to NIS 17 million in positive operating cash flow, compared to negative cash flow in the prior year. The company also saw its Adjusted EBITDA more than double to NIS 47 million, marking its twelfth consecutive half-year of positive Adjusted EBITDA, and reduced its net loss to NIS 37 million from NIS 73 million. These results reflect a robust recovery from the impact of the October 7, 2023 events, with resumed production and sales from its Nir Oz facility. Strategically, InterCure launched over 75 new GMP SKUs, expanded partnerships, and made key acquisitions including Botanico Ltd. and a strategic investment in Cannasoul R&D Ltd., while its CEO and a significant investor increased their stakes. This comprehensive positive report, especially the return to positive operating cash flow and strong EBITDA growth, is highly material for a small-cap company navigating geopolitical challenges and indicates significant operational improvement.
At the time of this announcement, INCR was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46M. The 52-week trading range was $0.68 to $1.77. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.